COMP <GO>
ICCC vs LLY // EV/EBITDA & P/E VALUATION
ImmuCell Corporation (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: ICCC 1
— LLY 11
▲ EV/EBITDA & P/E VALUATION LEADER: ICCC
LAST: $10.32 (-2.82%) • MKT CAP: $93.7M
valuation
35.9x
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ICCC VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ICCC | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.40% | 83.64% | -42.24 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.20% | 32.36% | -28.16 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 35.9x | 36.4x | -0.52 | ICCC | /valuation <GO> |
| Free Cash Flow Yield | 1.31% | 2.30% | -0.99 | LLY | /fcf-yield <GO> |
| Operating Margin | 6.00% | 40.21% | -34.21 | LLY | /operating-margins <GO> |
| Net Profit Margin | -3.80% | 31.90% | -35.70 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 4.30% | 45.51% | -41.21 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.28 | 9.29 | -5.01 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.5 | 66.6 | -16.12 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 26.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $93.7M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ICCC REV | LLY REV | ICCC GROSS % | LLY GROSS % | ICCC FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $27.6M | $65.18B | 41.4% | 83.0% | $1.2M | $16.81B |
| FY 2024 | $26.5M | $45.04B | 30.0% | 81.3% | -$107.8K | $8.82B |
| FY 2023 | $17.5M | $34.12B | — | 79.3% | -$4.7M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ICCC // BETA —
LLY // BETA 0.51